Investment

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

admin
admin

The Federal Trade Commission and seven states say Shkreli should be held in contempt

Source: MarketWatch

You Might Also Like

Social Security stopped our checks due to a hacked bank account. We’re relying on our church for help. What can we do?
The hidden messages the bond market is sending about the AI boom and the stock market
Amazon and Shopify make starkly different moves in the brewing battle over AI shopping
Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals
The best iPhones: which Apple smartphone is right for you, according to our expert
Share This Article
Previous Article South Africa vs Australia – First Test day five highlights
Next Article Sweden’s centre-left leader fails in second bid to form government
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *